Delivering A New Standard

Anthony W. Amato

Chief Executive Officer

After practicing law for several years, Tony started his career in pharmaceuticals in business development at Barr Labs. During his tenure at the company, Barr acquired proprietary women’s health products, Plan B and Paragard, and in-licensed transdermals, ophthalmics and nasal sprays, rapidly expanding beyond its generic solid oral dose portfolio. Barr was eventually acquired by Teva for $7.5B in 2008. Tony next headed up US business development at Lupin Pharmaceuticals and led the aggressive expansion into high margin brand products, diversifying Lupin’s product portfolio. In 2014 Tony joined Alvogen and rose to the position of Sr. Vice President Business Development and Alliance Management, completing multiple transactions and deploying over $500M capital in five years to expand the generic portfolio into injectables and inhalation drug forms and grow its branded business, Almatica, through the acquisition of highly profitable mature products and patent protected Psychiatry/CNS approved and pipeline products as well as biosimilars.

Tony was named CEO of Virtus in 2022 and is re-positioning the company by building verticals focused on retail and institutional generics, brands, consumer health and biosimilars, employing innovative business models and deal structures that will benefit its partners and, ultimately, patients.

Debra Cesard

Chief Financial Officer

Debra re-joined Virtus as Chief Financial Officer in March 2022, previously serving in that role through 2020. She is an accomplished financial manager with 25+ years of experience having previously worked for a “Big 4” accounting firm and emerging and established global brand and generic pharmaceutical companies including AdvaGen, Sandoz and Bristol-Myers Squibb. She possesses outstanding problem-solving abilities and impeccable integrity. A strategic-minded yet hands-on leader recognized for establishing cross functional collaboration as a business partner, initiating and managing change, developing high performing teams, as well as planning and executing corporate strategies and company- wide initiatives.

Debra is a Certified Public Accountant (inactive) and holds a Bachelor of Science in Accounting from Rutgers University.

Michael Proctor

Head of Promoted Products

Michael “Mickey” Proctor joined Virtus Pharmaceuticals, LLC in January 2022 as Head of Promoted Products. Mickey is an experienced veteran of the pharmaceutical industry with 43+ years of experience with brands and generics and start-up to global leading companies. He has served in executive leadership positions for 20+ years building strong performance teams among sales, marketing, managed care and account management. He created the commercial organization and launched the Suprax^® brand to exceed $100M in a generic market with no patent protection.

Mickey holds a Bachelors of Arts and Bachelors of Science in Marketing, Ohio State University.

Myrl Vossler

Head of Generics

Myrl joined the company in February 2022, and serves as Head of Generics, Virtus Pharmaceuticals. He has 15 years of experience leading sales, marketing, and supply chain operations with new and established ventures across the pharmaceutical industry. Myrl has developed and executed numerous programs to successfully penetrate markets, retain accounts and control inventory while strengthening business relationships and profitability across key customers.

Myrl holds a Bachelor of Science degree from the University of Central Missouri.

Matthew Prokopczyk

Senior Vice President, Quality and Regulatory

Matthew serves as Senior Vice President, Quality and Regulatory, Virtus Pharmaceuticals bringing 25+ years of experience with brand and generic pharmaceutical companies. Prior to joining Virtus in February 2022, he held leadership positions of Quality and Regulatory functions at Aphena, Amerigen, Alvogen, Dr. Reddy’s and Wyeth. He is an accomplished veteran of the industry with a proven track record of building and leading compliant, efficient, quality organizations.

Matthew holds an MBA in Finance and Business Economics from Fordham University, NY and a Bachelor of Science Degree from the College of Mount Saint Vincent, NY.

Ashleigh Preiss

Vice President, Operations and Alliance Management

Ashleigh joined Virtus in August 2013 and serves as the Vice President, Operations and Alliance Management. She has extensive experience with the Virtus supply chain and logistics processes and partnerships to maintain inventory and support excellent customer service. Prior to her current role Ashleigh held positions of increasing responsibility as: Director, Supply Chain, Associate Director, Procurement and Logistics and Customer Service Analyst.

Ashleigh holds a Bachelors of Arts in Communication Sciences and Disorders, University of South Florida and a Bachelors of Science, Sport Management, California University, PA and is currently studying for a Master of Science in Public Health, Applied Studies, University of Florida Graduate School of Public Health and Certification in Production and Inventory Management (APICS).

Sandra Shook

Director of Human Resources

Sandra joined Virtus in April 2017 and serves as the Director of Human Resources. She has 25+ years of experience in human resource functions, issues, employment law and organizational development. She has served in positions of increasing responsibility with a specialty and global generic pharmaceutical leader. She is responsible for all human resource functions and objectives that provide an employee-oriented; high performance culture that emphasizes empowerment, quality productivity, standards and the recruitment and ongoing development of a superior workforce.

Sandra holds a Bachelor of Science in Business Administration, Albright College, PA

David Friedman

Head, Strategy and Business Development

David has over 30 years experience providing a wide range of corporate advisory services to clients in healthcare and related industries. Clients have included life sciences companies Novartis, Boehringer Ingelheim, Endo, Par Pharmaceutical, Lannett, Lupin, JHP Pharmaceuticals, G&W Laboratories and Ranbaxy. David holds a BA (History - Honors) from Haverford College and an MBA (Finance) from The Wharton School, University of Pennsylvania. He also studied at the London School of Economics.